Steris stock holds above $230 as fiscal first-quarter earnings grow
Published on 08/21/2026 at 11:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Steris plc (IE00BFY8C754) stock traded at $236.91 on August 20, 2026, giving the healthcare sterilization and infection prevention specialist a market capitalization of $23.1 billion based on recent market data. Per the same pricing snapshot, the shares changed hands between an intraday low of $233.82 and a high of $238.74, leaving the price 1.3 percent above the session low and 0.8 percent below the high. These levels frame the latest move in the New York–listed stock after the company reported higher earnings for its current fiscal year.
Earnings grow in fiscal first quarter
In the fiscal first quarter of its 2027 financial year, Steris generated adjusted earnings of $2.59 per share, up 10.7 percent from the prior-year period, according to a detailed results review published on August 20, 2026 analysis of Steris fiscal first-quarter 2027 results. The same source indicates that revenue for the quarter reached $1.49 billion, representing 7.3 percent year-over-year growth in reported sales and highlighting steady demand across Steris core segments. On a constant-currency basis, organic revenue growth came in at 6.2 percent for the quarter, underscoring that most of the expansion was driven by volume and mix rather than foreign-exchange translation effects.
Adjusted income from operations for the fiscal first quarter rose 12 percent to $354.8 million, contributing to an adjusted operating margin of 23.8 percent as reported in the same earnings analysis further details on Steris margins and backlog. The 99-basis-point expansion in adjusted operating margin versus the prior-year quarter reflects the combined impact of higher volume, pricing actions, productivity measures and a favorable mix of services and consumables. Within the Healthcare segment, revenue reached $1.05 billion in the fiscal first quarter, while the company reported that services revenue grew 9.6 percent and consumables revenue increased 9.2 percent compared with the prior-year period.
Backlog and guidance support the outlook
The same fiscal first-quarter update noted that Steris healthcare backlog rose 10 percent to $444 million, providing additional visibility into future equipment and service deliveries discussion of Steris backlog and guidance. Management maintained fiscal 2027 guidance for reported revenue growth of 7 to 8 percent and constant-currency organic revenue growth of 6 to 7 percent, signaling confidence that demand trends and execution can sustain the recent pace of expansion. The company also reaffirmed its outlook for adjusted earnings of $11.10 to $11.30 per share in fiscal 2027, which, when compared with the annualized run rate implied by the first-quarter adjusted EPS of $2.59, leaves room for further earnings growth over the remainder of the year.
Tariff-related costs and refunds also featured in the quarter. Gross tariff costs amounted to $14 million in the fiscal first quarter, partially offset by $4 million in refunds as reported in the same analysis report on Steris tariff costs and refunds. Even with these headwinds, the expansion of adjusted margin by 99 basis points suggests that productivity initiatives and pricing have been sufficient to offset inflationary pressures and trade-related costs. For investors, the combination of mid-single-digit organic growth, double-digit adjusted income growth and expanding margins positions Steris as a company balancing top-line expansion with disciplined cost control in fiscal 2027.
Valuation and market positioning
Market data from a recent quote overview indicates that Steris shares are trading at a price-to-earnings ratio of 28.40 and offer a dividend yield of 1.08 percent based on the current share price and annualized dividend payments real-time snapshot of Steris stock price and valuation metrics. With a market capitalization of $23.1 billion at a share price of $236.91 as of August 20, 2026, the valuation reflects investors expectations for sustained earnings growth and the relative resilience of healthcare-related capital and service spending. The current share price also embeds the market assessment of the company ability to execute on its fiscal 2027 guidance, including the targeted 7 to 8 percent reported revenue growth and adjusted earnings in the low $11 per-share range.
One notable feature of the latest fiscal first-quarter performance is the relationship between revenue growth and margin expansion. Revenue increased 7.3 percent year-over-year to $1.49 billion, while adjusted income from operations climbed 12 percent to $354.8 million, implying that earnings grew faster than sales as operating leverage and mix improvements took effect overview of Steris revenue and income growth in Q1 fiscal 2027. This dynamic suggests that the company is converting incremental revenue into profit more efficiently than in the prior-year period, which supports the higher adjusted operating margin of 23.8 percent and may help underpin the current valuation multiple if the trend continues.
Sterilization and infection prevention solutions
Steris core business spans sterilization, decontamination and infection prevention solutions for healthcare and life-science customers, including capital equipment, consumables and related services. In the fiscal first quarter, the Healthcare segment delivered $1.05 billion of the $1.49 billion total revenue, underscoring the importance of hospitals and healthcare providers as primary customers breakdown of Steris healthcare segment performance. Services revenue within Healthcare grew 9.6 percent and consumables revenue increased 9.2 percent year-over-year, suggesting that installed equipment bases are driving recurring revenue streams through maintenance, sterilization cycles and related supplies.
Capital equipment revenue in the Healthcare segment rose 1.4 percent in the fiscal first quarter compared with the prior-year period, a slower pace than services and consumables as shipment timing affected the quarter details on Steris capital equipment revenue in the latest quarter. However, the 10 percent increase in healthcare backlog to $444 million indicates that demand for equipment remains healthy and that revenue recognition will follow as projects are delivered and installed. For customers, Steris offerings support compliance with sterilization standards and infection-control protocols, while for investors the mix of equipment and recurring services provides a blend of up-front and ongoing revenue.
Steris stock price context
Based on the latest available quote, Steris stock closed at $236.91 on August 20, 2026, within an intraday range of $233.82 to $238.74 for that session intraday trading range and closing price for Steris shares. With the shares trading modestly above the session low and slightly below the high, the price action reflects a relatively stable response to the recent fiscal first-quarter earnings report and reaffirmed guidance. The combination of a $23.1 billion market capitalization, a 28.40 price-to-earnings ratio and a 1.08 percent dividend yield provides a snapshot of how the market is currently valuing Steris earnings stream and balance of growth and income as of late August 2026.
Read more
Healthcare sterilization platforms
Within its Healthcare segment, Steris offers integrated sterilization platforms that combine capital equipment, such as sterilizers and washers, with consumables and services to support day-to-day hospital operations. The fiscal first-quarter data showing 9.6 percent growth in services revenue and 9.2 percent growth in consumables revenue indicates that customers are continuing to utilize these platforms at higher levels than in the prior-year period service and consumable growth trends in Steris Healthcare segment. For hospitals and surgical centers, such platforms aim to ensure that instruments and equipment are sterilized efficiently and consistently, helping to reduce infection risk and support patient safety.
Steris stock and recent trading levels
In the context of the broader healthcare sector, Steris stock trading at $236.91 as of the August 20, 2026 session places the company in the mid-cap to large-cap range with a market capitalization of $23.1 billion market capitalization and valuation metrics for Steris. The stock price, combined with the adjusted earnings guidance of $11.10 to $11.30 per share for fiscal 2027, implies that investors are assigning a forward valuation multiple that reflects expectations for mid-single-digit organic growth and continued margin expansion. For income-focused investors, the indicated dividend yield of 1.08 percent adds a modest income component to the total return profile, complementing the potential for capital appreciation if Steris meets or exceeds its fiscal 2027 targets.
Fact box
Company: Steris plc
ISIN: IE00BFY8C754
Ticker: STE
Exchange: NYSE
Price (as of August 20, 2026, 4:00 p.m. ET): $236.91 USD
Market cap: $23.1 billion (as of August 20, 2026)
Sector / Industry: Healthcare equipment and services
Index membership: S&P 500
